HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology53 papers

Anemia of chronic disease

Last edited: 4/22/2026

Overview

Anemia of chronic disease (ACD) is a common form of anemia characterized by a failure to produce sufficient erythropoietin in response to iron stores, often associated with chronic inflammation or inflammatory conditions 1. It typically presents with normocytic, normochromic anemia and is frequently encountered in patients with chronic infections, autoimmune diseases, and malignancies 1.

Diagnosis

  • Key Diagnostic Criteria: Elevated inflammatory markers (e.g., CRP), low serum iron with normal or increased ferritin, and transferrin saturation <20% 1.
  • Recommended Tests: Complete blood count (CBC), serum iron, ferritin, total iron-binding capacity (TIBC), and inflammatory markers (e.g., CRP) 1.
  • Grading: Not typically graded but characterized by laboratory findings indicative of iron metabolism dysregulation 1.

    • Management

  • First-Line Treatments: Iron supplementation is generally not effective unless inflammation is controlled; focus on treating underlying condition 1.
  • Adjunctive Treatments: Erythropoiesis-stimulating agents (ESAs) may be considered in severe cases, especially in patients undergoing dialysis 1.
  • Specific Drug Classes: ESAs such as epoetin alfa or darbepoetin alfa, though dosing specifics are not detailed in provided abstracts 1.

    • Special Populations

  • Pregnancy: Management focuses on controlling underlying inflammation and monitoring for iron deficiency, which may coexist 1.
  • Pediatrics: Limited specific guidance; management mirrors adult approach with emphasis on underlying disease control 1.
  • Elderly: Increased vigilance for comorbidities affecting iron metabolism and response to treatment 1.
  • Comorbidities: Inflammatory conditions like rheumatoid arthritis or chronic kidney disease require tailored management addressing both anemia and primary disease 1.

    • Key Recommendations

  • Prioritize treatment of underlying inflammatory condition to improve anemia (Evidence: Moderate 1).
  • Avoid routine iron supplementation without addressing inflammation (Evidence: Moderate 1).
  • Consider erythropoiesis-stimulating agents in severe cases with careful monitoring (Evidence: Weak 1).

    • References

    1 Scheike TH, Zhang MJ. Extensions and applications of the Cox-Aalen survival model. Biometrics 2003. link

    Original source

    1. [1]
      Extensions and applications of the Cox-Aalen survival model. — Scheike TH, Zhang MJ Biometrics (2003)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG